Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 9/20 | 0.60 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.60 |
| ▸ | HTR6 | P50406 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17259313 | 0.85 | KCNH2 (0.49) | KCNH2CACNA1GCACNA1HHTR6 | |
| SCHEMBL3300740 | 0.85 | KCNH2 (0.60) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 | |
| SCHEMBL17259259 | 0.85 | KCNH2 (0.60) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 | |
| SCHEMBL17259227 | 0.82 | KCNH2 (0.67) | KCNH2CACNA1GCACNA1HHTR6 | |
| SCHEMBL13423350 | 0.79 | KCNH2 (0.53) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 | |
| SCHEMBL17259317 | 0.78 | HTR6 (0.48) | KCNH2CACNA1GCACNA1HHTR6 | |
| SCHEMBL23402955 | 0.78 | KCNH2 (0.52) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 | |
| SCHEMBL17259273 | 0.78 | KCNH2 (0.53) | KCNH2CACNA1GCACNA1HHTR6 | |
| SCHEMBL16808042 | 0.77 | KCNH2 (0.52) | KCNH2CACNA1GCACNA1HHTR6 | |
| SCHEMBL28645869 | 0.76 | CNR1 (0.42) | KCNH2CACNA1GCACNA1HHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | KCNH2 33/4885CACNA1G 3/4885CACNA1H 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.